RLS-003 for Acute Kidney Injury (AKI)

  • Strong exclusivity position (issued patent)
  • Potential for $1.5B+ drug in U.S. alone (300,000 diagnosed annually)
  • Major global unmet need; leading cause of chronic kidney disease and end-stage renal disease; AKI+CKD+ESRD = >$30B annually - more than a quarter of the Medicare Budget
  • RLS-003 has been used in humans for decades for a completely unrelated indication – never approved in the U.S. for any indication
  • Well-understood mechanism of action for AKI – supported by AKI mouse models
  • RLS-003 is ready to enter Phase II efficacy studies

Additional opportunities in our queue



Cancer solid tumor drug resistance Co-administration or two drugs with existing targeted cancer drugs
Autoimmune disorders - initially Lupus Nephritis Foreign triage
Alzheimer's Disease Repurposed clinical Type-II anti-Diabetic
p53-based Cancer therapy Combination of two existing drugs
Wound healing Repurposed antihypertensive
Acute Myeloid Leukemia Existing drug approved outside U.S.
Anterior Uveitis Repurposed ophthalmic compound
Peripheral Artery Disease Formulation of known compounds
Autism Spectrum Disorder Small molecule used for other CNS disorders